Clinical-stage focus Pliant Therapeutics is a clinical-stage biopharma specializing in integrin-based therapeutics with ongoing Phase 1 data presentations and multiple conference engagements. This indicates receptivity to collaboration on translational research, external partnerships, and potential licensing or co-development deals around lead candidates.

Strategic partnerships High engagement in major oncology and general medical conferences (ASCO, AACR, Oppenheimer healthcare) suggests opportunities to approach for strategic partnerships, joint development programs, or sponsored research collaborations with pharma companies seeking integrin-targeted therapies and TGF-β modulation approaches.

Clinical potential監 Lead program PLN-101095 is advancing in solid tumors with upcoming data presentations, signaling opportunities for CROs, contract manufacturing, and translational service providers to support clinical trial activities, biomarker strategies, and AML/oncology-specific assay development.

Financials & scale With a substantial funding runway ($695M) and revenue in the low millions, Pliant has capital to pursue expansion, out-licensing, or strategic collaborations. This equity position may be favorable for co-development or milestone-driven partnerships with larger biotechs.

Talent & location South San Francisco headquarters and a leadership hire as Chief Technical Officer indicate a maturing biopharma setup with potential for regional partnerships, academic collaborations, and specialized biotech vendors to support GMP manufacturing, analytics, and translational science initiatives.